Article Contents ::
- 1 Details About Generic Salt :: Zileuton
- 2 Main Medicine Class:: Leukotriene receptor inhibitor
- 3 (zill-LOO-tuhn) Zyflo Class: Leukotriene receptor inhibitor
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Zileuton
Main Medicine Class:: Leukotriene receptor inhibitor
(zill-LOO-tuhn)
Zyflo
Class: Leukotriene receptor inhibitor
Drugs Class ::
Action Attenuates bronchoconstriction by inhibiting leukotriene-dependent smooth muscle contractions.
Indications for Drugs ::
Indications Prophylaxis and chronic treatment of asthma.
Drug Dose ::
Route/Dosage
ADULTS & CHILDREN ³ 12 YR: PO 600 mg qid.
Contraindication ::
Contraindications Active liver disease; elevations in transaminases greater than or equal to three times the upper limit of normal.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy in pediatric patients < 12 yrs of age not established. Acute asthma attacks: Not indicated for treatment of acute asthma attacks. Continue therapy during acute exacerbations of asthma. Hepatotoxicity: Elevations in liver function tests may occur. Use with caution in patients who consume substantial quantities of alcohol or who have history of liver disease. Monitor hepatic transaminases at initiation of, and during therapy. Hematologic: Transient decreases in WBCs may occur.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CNS: Pain; dizziness; insomnia; somnolence; malaise; nervousness; hypertonia. EENT: Conjunctivitis. GI: Abdominal pain; dyspepsia; nausea; vomiting; constipation; flatulence. GU: Urinary tract infection; vaginitis. HEPA: Elevated liver function tests. OTHER: Asthenia; myalgia; arthralgia; chest pain; fever; lymphadenopathy; muscle rigidity; pruritis.
Drug Mode of Action ::
Action Attenuates bronchoconstriction by inhibiting leukotriene-dependent smooth muscle contractions.
Drug Interactions ::
Interactions Propranolol, theophylline, warfarin: Effects of these agents may be increased.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of liver disease or alcohol consumption.
- Assess patient’s respiratory status prior to and during therapy.
- Ensure that liver function tests are monitored during therapy.
- Monitor patient medication for effectiveness and side effects, including signs and symptoms of liver dysfunction.
Drug Storage/Management ::
Administration/Storage
- Available only in PO form.
- Store tablets at room temperature (20° to 25°C; 68° to 77°F).
- Keep in tightly sealed container, protected from light.
- May be taken with meals and at bed time.
Drug Notes ::
Patient/Family Education
- Inform the patient that this medication is for long-term treatment of asthma.
- Instruct patient to take the medication exactly as prescribed even when they are free of symptoms.
- Advise patient to take medication 4 times/day with each meal and at bedtime.
- Warn the patient that this is not a bronchodilator and should not be used for the treatment of acute asthma attacks. However, advise the patient to continue during acute asthma attacks.
- Instruct the patient to continue to take other asthma medications as prescribed.
- Instruct the patient to avoid taking other medication, including otc, without discussing it with his/her health care provider.
- Advise patient that elevation of liver enzyme is most serious side effect and that he/she must have liver function tests periodically. Instruct the patient to notify his/her health care provider if experiencing any signs or symptoms of liver disease: Flu-like symptoms; nausea; right upper quadrant pain; fatigue; lethargy; pruritis; jaundice.
- Instruct patient to notify health care provider if the use of short-acting bronchodilators increases or if more than the maximal number of inhalations of short-acting bronchodilators are needed.